BioMarin director Plenge reports no BMRN holdings

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an initial statement of beneficial ownership (Form 3) for Robert M. Plenge, who is identified as a director of the company.

Rhea-AI Filing Summary

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an initial statement of beneficial ownership (Form 3) for Robert M. Plenge, who is identified as a director of the company. The filing reports no transactions, no derivative positions, and no share holdings for him at this time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filed for BMRN disclose about Robert M. Plenge?

It discloses that Robert M. Plenge is a director of BIOMARIN PHARMACEUTICAL INC and, as of this filing, he reports no share holdings, no transactions, and no derivative positions in the company’s securities.

Does the BMRN Form 3 show any shares owned by Robert M. Plenge?

No. The Form 3 for BIOMARIN PHARMACEUTICAL INC reports zero share holdings for director Robert M. Plenge at the time of the filing, with no common stock or derivative securities listed.

Are there any buy or sell transactions reported for BMRN in this Form 3?

No. The filing’s transaction summary shows 0 buy transactions, 0 sell transactions, and 0 net shares traded, indicating no reportable transactions by Robert M. Plenge in BIOMARIN PHARMACEUTICAL INC securities to date.

Does the BMRN Form 3 indicate use of a Rule 10b5-1 trading plan?

No. The Form 3 data show no Rule 10b5-1 trading plan affirmation and no related footnote disclosure, consistent with there being no reported transactions in BIOMARIN PHARMACEUTICAL INC securities.

What is the significance of a Form 3 for BMRN investors?

A Form 3 signals that an insider, here director Robert M. Plenge, has become a reporting person for BIOMARIN PHARMACEUTICAL INC. This particular filing shows an initial status with no reported ownership or trades in the company’s securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:48 PM EDT Accepted by SEC EDGAR 09/14/2026 - 06:48 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Plenge Robert M

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/10/2026

3. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Tae Sang Yoo, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)